Skip to main content

Table 2 Patients with malignant primary disease and oncological therapy in two hospices

From: Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis

Category and related p-valuea Hospice 1 (H1) Hospice 2 (H2) Total
Patients with oncological therapy in a hospice (p < 0.01) 33 11% 6 2% 39 6%
Age in years (average) 69 (range: 44–93) 68 (range: 56–87) 68 (range: 44–93)
Residence time in days 67 (range: 4–440) 44 (range: 4–100) 55 (range: 4–440)
Gender
 Male 11 33% 1 17% 12 31%
 Female 22 67% 5 83% 27 69%
Malignant disease (primary diagnosis)
 Bronchial carcinomas 5 15% 1 17% 6 15%
 Gastrointestinal cancers 7 21% 0 0% 7 18%
 Gynecological cancers 10 30% 4 67% 14 36%
 Brain cancers 1 3% 1 17% 2 5%
 ENT tract cancers 1 3% 0 0% 1 3%
 Other cancer (bone cancers, thyroid carcinomas, skin malignomas, cancer of unknown pirmary) 0 0% 0 0% 0 0%
 Urological cancers 6 18% 0 0% 6 15%
 Hematological systemic diseases 3 9% 0 0% 3 8%
Indication of oncological therapies (multiple indications per patient, where applicable) 41 6 47
 Dyspnea due to anaemia (p = 0.58) 10 24% 0 0% 10 21%
 Diarrhea due to cancer disease (p = 1.00) 2 5% 0 0% 2 4%
 Bone pain (p = 0.65) 13 32% 2 33% 15 32%
 Meningeal cancer manifestation (p = 1.00) 1 2% 0 0% 1 2%
 Continuation of ongoing anti-proliferative therapy (p = 0.01) 0 0% 2 33% 2 4%
 Nausea/vomiting due to cancer disease (p = 1.00) 1 2% 0 0% 1 2%
 Complications due to leukocytosis (p = 1.00) 3 7% 0 0% 3 6%
 Pain therapy (p = 0.12) 4 10% 2 33% 6 13%
 Other complications due to cancer disease (p = 1.00) 3 7% 0 0% 3 6%
Oncological therapy (multiple treatment, where applicable) 41 6 47
 Anti-hormonal therapy (p = 0.27) 5 12% 2 33% 7 15%
 Targeted therapies (antibody therapy, tyrosine kinase inhibitors, somatostatin analogues; p = 0.44) 4 10% 2 33% 6 13%
 Chemotherapy (p = 0.01) 6 15% 0 0% 6 15%
 Radiotherapy (p = 0.01) 6 15% 0 0% 6 13%
 Bisphosphonates (p = 0.02) 10 24% 2 33% 12 26%
 Transfusions (p < 0.01) 10 24% 0 0% 10 21%
Clinical course
 Discharge 2 6% 1 17% 3 8%
 Hospitalization 1 3% 1 17% 2 5%
For survival time see Fig. 2       
  1. a Refers to the comparison of the two hospices